Classifications: psychotherapeutic; carbamate; anxiolytic; sedative-hypnotic; Therapeutic: antianxiety; sedative-hypnotic
Pregnancy Category: D
Controlled Substance: Schedule IV
200 mg, 400 mg tablets
Carbamate derivative. CNS depressant actions similar to those of barbiturates. Acts on multiple sites in CNS and appears
to block corticothalamic impulses.
Antianxiety agent. Hypnotic doses suppress REM sleep.
To relieve anxiety and tension of psychoneurotic states and as adjunct in disease states associated with anxiety and tension.
Also used to promote sleep in anxious, tense patients.
History of hypersensitivity to meprobamate or related carbamates; ethanol intoxication; history of acute intermittent porphyria;
pregnancy (category D), lactation, children <6 y.
Impaired kidney or liver function; convulsive disorders; history of alcoholism or drug abuse; patients with suicidal tendencies.
Route & Dosage
Adult: PO 1.21.6 g/d in 34 divided doses (max: 2.4 g/d)
Child: PO 100200 mg b.i.d. or t.i.d.
Adult: PO 400800 mg
Geriatric: PO 200 mg 23 times/d
Child: PO 200 mg
- Give with food to minimize gastric distress.
- Treatment physical dependence by gradual drug withdrawal over 12 wk to prevent onset of withdrawal symptoms.
- Store at 15°30° C (59°86° F) unless otherwise specified by manufacturer.
Adverse Effects (≥1%)Body as a Whole:
Allergy or idiosyncratic reactions (itchy, urticarial, or erythematous maculopapular rash; exfoliative dermatitis,
petechiae, purpura, ecchymoses, eosinophilia, peripheral edema, angioneurotic edema, adenopathy, fever, chills, proctitis,
bronchospasm, oliguria, anuria, Stevens-Johnson syndrome
); anaphylaxis. CNS: Drowsiness
dizziness, vertigo, slurred speech, headache, weakness, paresthesias, impaired visual accommodation, paradoxic euphoria
and rage reactions, seizures in epileptics, panic reaction, rapid EEG activity. CV:
Hypotensive crisis, syncope, palpitation, tachycardia, arrhythmias, transient ECG changes, circulatory collapse
(toxic doses). GI:
Anorexia, nausea, vomiting, diarrhea. Hematologic: Aplastic anemia
(rare): leukopenia, agranulocytosis, thrombocytopenia,
exacerbation of acute intermittent porphyria. Respiratory: Respiratory depression.
Diagnostic Test Interference
Meprobamate may cause falsely high urinary steroid determinations. Phentolamine tests may be falsely positive; meprobamate should be withdrawn at least 24 h and preferably 4872 h before the test.
InteractionsDrug: Alcohol entacapone, tricyclic antidepressants
, sedating antihistamines
, pentazocine, tramadol, maoi
may potentiate CNS depression
. Herbal: Kava, valerian
may potentiate sedation.
Well absorbed from GI tract. Peak:
13 h. Onset:
1 h. Distribution:
Uniformly throughout body; crosses placenta. Metabolism:
Rapidly in liver. Elimination:
Renally excreted; excreted in breast milk. Half-Life:
Assessment & Drug Effects
- Supervise ambulation, if necessary. Older adults and debilitated patients are prone to oversedation and to the hypotensive
effects, especially during early therapy.
- Utilize safety precautions for hospitalized patients. Hypnotic doses may cause increased motor activity during sleep.
- Consult physician if daytime psychomotor function is impaired. A change in regimen or drug may be indicated.
- Withdraw gradually in physically dependent patients to prevent preexisting symptoms or withdrawal reactions within 1248
h: Vomiting, ataxia, muscle twitching, mental confusion, hallucinations, convulsions, trembling, sleep disturbances, increased
dreaming, nightmares, insomnia. Symptoms usually subside within 1248 h.
Patient & Family Education
- Take drug as prescribed. Psychic or physical dependence may occur with long-term use of high doses.
- Be aware that tolerance to alcohol will be lowered.
- Make position changes slowly, especially from lying down to upright; dangle legs for a few minutes before standing.
- Avoid driving or engaging in hazardous activities until response to drug is known.
- Report immediately onset of skin rash, sore throat, fever, bruising, unexplained bleeding.